Special Issue

Advances in Enzyme Inhibitors and Protein Degraders as Anticancer Agents

Message from the Guest Editors

Cancer is known to be one of the leading causes of death worldwide, with approximately 20% of the population being diagnosed with cancer in their lifetime. Many oncogenic enzyme targets (i.e. KRAS, KATs) have been labelled "undruggable" in the past; however, advances in chemical biology and molecular biology have yielded tools that can drug these "undruggable" targets. One such technology that is rapidly advancing through clinical trials is a class of compounds called PROTACs (PROteolysis-TArgeting Chimeras). The use of antibody-drug conjugates (ADCs) as anticancer agents is rising exponentially. More than ten ADCs have already gained Food and Drug Administration (FDA) approval, and we expect this number to rise significantly in the coming years given the fact that there are hundreds of ADCs currently being investigated in clinical trials. Despite the numerous challenges faced by those that develop anticancer therapeutics, we envisage that the next breakthrough anticancer agent is just around the corner.

Guest Editors

Dr. David J. Leaver

- 1. Gulbali Institute, Charles Sturt University, Wagga Wagga, NSW, Australia
- 2. School of Dentistry and Medical Sciences, Charles Sturt University, Wagga Wagga, NSW, Australia

Dr. Li Li

Gulbali Institute, Charles Sturt University, Wagga Wagga, NSW, Australia

Deadline for manuscript submissions

31 December 2025



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/242506

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

